Condition: Intermediate Risk Prostate Cancer · High Risk Prostate Cancer · Prostate Cancer · Sponsor: Martin T. King, MD, PhD
This research study is for men with intermediate- or high-risk prostate cancer who are planning to receive hormone therapy and radiation treatment. The purpose of the study is to see whether a special type of diagnostic imaging done during hormone therapy can help doctors more accurately target remaining cancer with radiation, while avoiding areas that may no longer need extra treatment. All participants will receive standard hormone therapy and radiation therapy, along with three imaging scans, over a six-month period. The information gained from this study may help make prostate cancer radiation treatment more precise and reduce side effects for future patients.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Brigham and Women's Hospital | Boston, Massachusetts, United States | Not Yet Recruiting |
| Dana Farber Cancer Institute | Boston, Massachusetts, United States | Not Yet Recruiting |
| Dana-Farber/Brigham and Women's Cancer Center at Milford Regional Medical Center | Milford, Massachusetts, United States | Recruiting |
| Dana-Farber/Brigham and Women's Cancer Center in Clinical Affiliation with South Shore Hospital | Weymouth, Massachusetts, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07393867